William Blair Issues Pessimistic Forecast for NAMS Earnings

NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Research analysts at William Blair lowered their Q4 2024 earnings estimates for shares of NewAmsterdam Pharma in a report released on Wednesday, November 6th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of ($0.51) for the quarter, down from their previous forecast of ($0.39). The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.79) per share. William Blair also issued estimates for NewAmsterdam Pharma's Q1 2025 earnings at ($0.49) EPS, Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.99) EPS, FY2026 earnings at ($2.07) EPS and FY2027 earnings at ($2.32) EPS.

NAMS has been the topic of several other reports. Piper Sandler reissued an "overweight" rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Royal Bank of Canada reaffirmed an "outperform" rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $33.80.

NewAmsterdam Pharma Price Performance

NAMS stock traded up $0.47 during mid-day trading on Monday, hitting $24.59. The stock had a trading volume of 538,680 shares, compared to its average volume of 262,282. NewAmsterdam Pharma has a 52 week low of $8.64 and a 52 week high of $26.35. The firm has a fifty day simple moving average of $17.67 and a 200 day simple moving average of $18.48.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors have recently added to or reduced their stakes in the business. Artal Group S.A. acquired a new stake in NewAmsterdam Pharma during the 1st quarter valued at approximately $18,920,000. Janus Henderson Group PLC acquired a new stake in shares of NewAmsterdam Pharma during the first quarter worth $15,018,000. Decheng Capital LLC bought a new position in NewAmsterdam Pharma during the second quarter worth $7,684,000. Millennium Management LLC lifted its holdings in NewAmsterdam Pharma by 23.0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company's stock valued at $22,388,000 after buying an additional 217,902 shares during the period. Finally, Deerfield Management Company L.P. Series C boosted its position in NewAmsterdam Pharma by 30.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company's stock valued at $16,698,000 after acquiring an additional 202,250 shares during the last quarter. 89.89% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 45,000 shares of the business's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.